<?xml version="1.0" encoding="UTF-8" standalone="yes"?><?xml-stylesheet type="text/xsl" href="/oai-pmh-repository/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2026-10-15T09:48:30Z</responseDate>
    <request verb="GetRecord" identifier="oai:data.mendeley.com/xkc9x7v2sr.1" metadataPrefix="oai_dc">https://data.mendeley.com/oai</request>
    <GetRecord>
        <record>
            <header>
                <identifier>oai:data.mendeley.com/xkc9x7v2sr.1</identifier>
                <datestamp>2026-09-01T13:36:19Z</datestamp>
            </header>
            <metadata><oai_dc:dc xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <dc:creator>Habib, Jakaria </dc:creator>
    <dc:title>Longitudinal eGFR Trajectory and Survival Benchmark Dataset for Chronic Kidney Disease (SMART-C Cohort)</dc:title>
    <dc:publisher>Mendeley Data</dc:publisher>
    <dc:description>1. Scientific Overview &amp; Objective
This benchmark dataset, developed under the Reproducible Longitudinal Dynamical Patterns (RLDP) framework, provides high-density, multi-year clinical time-series for evaluating continuous-time trajectory forecasting, state-space estimation, and out-of-sample prognostic risk models in Chronic Kidney Disease (CKD). Longitudinal modeling of renal function requires overcoming significant observational challenges, including sparse and irregularly spaced visits, analytical measurement noise, and non-linear trajectory decay. This dataset establishes a standardized, fully reproducible benchmark for machine learning and dynamical systems in nephrology.

2. Cohort Specification &amp; Clinical Design
The dataset comprises N = 5,000 adult CKD patients prospectively tracked across a 3-year timeline (Days 1 to 1,096), generating 41,800 longitudinal laboratory evaluations (mean: 8.36 visits per patient; range: 2 to 14 visits). The primary continuous biomarker is Estimated Glomerular Filtration Rate (eGFR, mL/min/1.73m2). Baseline eGFR across the cohort is 55.70 +/- 17.97 mL/min/1.73m2 (range: 6.0 to 115.0 mL/min/1.73m2). Randomization is structured 1:1 into active intervention (n = 2,501) and control placebo (n = 2,499), stratified at screening by baseline disease severity into three clinical strata:
- Screening eGFR 30 to &lt;45 mL/min/1.73m2 (n = 1,497, 29.9%)
- Screening eGFR 45 to &lt;60 mL/min/1.73m2 (n = 1,466, 29.3%)
- Screening eGFR 60 to &lt;90 mL/min/1.73m2 (n = 2,037, 40.7%)
Baseline concurrent GLP-1 receptor agonist therapy is documented in 24.9% of participants.

3. File Structure &amp; Data Dictionary
The archive contains two harmonized CSV files:
- baseline.csv (5,000 records): usubjid (patient ID), trt01pn (arm: 1=active, 0=placebo), randfl (randomized), ittfl (intent-to-treat), trtfl (treated), blgfr (baseline eGFR), blglp1 (baseline GLP-1 status), strata (screening renal category).
- followup.csv (41,800 records): usubjid, randfl, ittfl, trtfl, anl01fl, aval (observed visit eGFR), base (baseline eGFR), paramcd (GFRBSCRT), param, ady (analysis day: 1 to 1096), avisitn, avisit (protocol visit name: BASELINE, WEEK 3, WEEK 13, etc.).

4. Data Quality &amp; Harmonization Audit
Automated audit confirms: (a) 0.0% single-visit static records (all multi-year trajectories up to 3 years); (b) 0.0% acute ICU stays (&lt;= 14 days); (c) 0.0% pediatric records (age &gt;= 18); (d) hyperfiltration capped at eGFR &lt;= 140; and (e) 0.0% missingness on protocol eGFR.

5. Intended Benchmark Applications
Designed for benchmarking: (1) Sparse Functional Data Analysis (PACE / FPCA) via BLUP conditional expectation; (2) Continuous-Time State-Space Kalman Filtering (CT-SSM) with Maximum Likelihood estimation and closed-form uncertainty bounds; (3) Empirical Bayes Linear Mixed-Effects Models (EB-LMM); (4) Neural Velocity ODEs; and (5) Out-of-sample survival models for severe renal failure progression (eGFR &lt; 30 mL/min/1.73m2).</dc:description>
    <dc:subject>Computer Science</dc:subject>
    <dc:subject>Health Informatics</dc:subject>
    <dc:subject>Medical Informatics</dc:subject>
    <dc:type>Dataset</dc:type>
    <dc:identifier>doi:10.17632/xkc9x7v2sr.1</dc:identifier>
    <dc:identifier>oai:data.mendeley.com/xkc9x7v2sr.1</dc:identifier>
    <dc:rights>Creative Commons Attribution 4.0 International</dc:rights>
    <dc:rights>http://creativecommons.org/licenses/by/4.0</dc:rights>
    <dc:relation>https://data.mendeley.com/datasets/xkc9x7v2sr</dc:relation>
    <dc:date>2026-09-01T13:36:19Z</dc:date>
</oai_dc:dc></metadata>
        </record>
    </GetRecord>
</OAI-PMH>
